U.S. Hospital Acquired Infections Diagnostics Market Size & Outlook
Related Markets
U.S. hospital acquired infections diagnostics market highlights
- The U.S. hospital acquired infections diagnostics market generated a revenue of USD 937.0 million in 2024 and is expected to reach USD 1,006.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 1.2% from 2025 to 2030.
- In terms of segment, conventional was the largest revenue generating test type in 2024.
- Molecular is the most lucrative test type segment registering the fastest growth during the forecast period.
Hospital acquired infections diagnostics market data book summary
| Market revenue in 2024 | USD 937.0 million |
| Market revenue in 2030 | USD 1,006.6 million |
| Growth rate | 1.2% (CAGR from 2025 to 2030) |
| Largest segment | Conventional |
| Fastest growing segment | Molecular |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Molecular, Conventional |
| Key market players worldwide | BioMerieux SA, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG ADR, Becton Dickinson & Co, Qiagen NV, Thermo Fisher Scientific Inc, Meridian Bioscience, Hologic, Inc. |
Other key industry trends
- In terms of revenue, U.S. accounted for 21.8% of the global hospital acquired infections diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. hospital acquired infections diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 1,006.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hospital Acquired Infections Diagnostics Market Scope
Hospital Acquired Infections Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Hologic, Inc. | View profile | - | - | - |
| Abbott | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Meridian Bioscience | View profile | 501-1000 | Cincinnati, Ohio, United States, North America | http://meridianbioscience.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Siemens Healthineers AG ADR | View profile | 71400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | https://www.siemens-healthineers.com |
| BioMerieux SA | View profile | 13982 | Marcy l’Etoile, Lyon, France, 69280 | http://www.biomerieux.com |
| Becton Dickinson & Co | View profile | 73000 | 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 | https://www.bd.com |
U.S. hospital acquired infections diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hospital acquired infections diagnostics market will help companies and investors design strategic landscapes.
Conventional was the largest segment with a revenue share of 53.5% in 2024. Horizon Databook has segmented the U.S. hospital acquired infections diagnostics market based on molecular, conventional covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is witnessing a significant rise in the number of HAI cases. According to the Centers for Disease Control and Prevention (CDC), HAIs affect approximately 1 in 25 hospital patients in the U.S. each year.
Common types of HAIs include surgical site infections, central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia. In July 2024, a study by the National Institutes of Health revealed an increase in both hospital-acquired infections and antibiotic resistance.
The findings are based on data collected from 120 U.S. hospitals over a five-year period, spanning January 2018 to December 2022, which included the COVID-19 pandemic. The increasing prevalence of HAIs leads to longer hospital stays, higher healthcare costs, and greater patient morbidity and mortality, necessitating effective prevention and control measures.
Reasons to subscribe to U.S. hospital acquired infections diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. hospital acquired infections diagnostics market databook
-
Our clientele includes a mix of hospital acquired infections diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hospital acquired infections diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. hospital acquired infections diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
US Test Type - Hospital Acquired Infections Diagnostics Market size, 2024 - 2030 (US$M)
U.S. Hospital Acquired Infections Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
